

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in this application.

**Listing of Claims:**

Claims 1-68 (canceled).

Claim 69 (currently amended): A method for inducing bone ~~tissue~~ formation at a locus accessible to at least one progenitor cell of a mammal, ~~wherein the tissue is selected from the group consisting of bone, cartilage, tendon/ligament and neural tissue,~~ comprising the step of implanting a morphogenic device, ~~whereby~~ wherein the morphogenic device induces bone ~~tissue~~ formation from the progenitor cell in the mammal, and wherein the morphogenic device ~~comprising~~ comprises:

a) an implantable biocompatible carrier,  
b) OP-1 disposed in the carrier, and capable of inducing bone ~~tissue~~ formation when accessible to the progenitor cell, and

c) ~~a morphogenic protein stimulatory factor (MPSF) selected from the group consisting of IGF-I, hydrocortisone,~~

~~insulin and parathyroid hormone, wherein said MPSCF is~~ disposed in the carrier, and wherein said MPSCF IGF-I is at a concentration effective to synergistically stimulate the ability of OP-1 to induce bone ~~tissue~~ formation from the progenitor cell.

Claim 70 (withdrawn): The method according to claim 69, wherein the locus is a jaw bone for use in periodontal or dental reconstructive procedures.

Claim 71 (previously presented): The method according to claim 69, wherein the locus is a bone defect selected from the group consisting of a fracture, a non-union fracture, a fusion and a bony void.

Claims 72-101 (canceled).

Claim 102 (previously presented): The method according to claim 69, wherein the carrier comprises heparin or a salt thereof.

Claims 103-107 (canceled).

Claim 108 (previously presented): The method according to claim 69, wherein OP-1 is capable of inducing the progenitor cell to form endochondral or intramembranous bone.

Claims 109-115 (canceled).

Claim 116 (currently amended): The method according to claim 69, wherein OP-1 is present in a pharmaceutical composition at a concentration of at least about 1 ng/ml, and the ~~morphogenic protein stimulatory factor~~ IGF-I is present in the pharmaceutical composition at a concentration of at least about 0.01 ng/ml.

Claim 117 (currently amended): The method according to claim 69, wherein OP-1 is present in a pharmaceutical composition at a concentration of from about 1 ng/ml to about 500 ng/ml and ~~the morphogenic protein stimulatory factor is~~ IGF-I and is present in the pharmaceutical composition at a concentration of from about 0.1 ng/ml to about 50 ng/ml.

Claims 118-122 (canceled).